|
| Home : Angiochem and Xinogen to Enter License Agreement |
|
Jan 04
2018 |
Angiochem and Xinogen to Enter License Agreement |
|
HONG KONG, CHINA and MONTREAL, QC--(Marketwired - January 03, 2018) - Angiochem Inc. and Xinogen (Hong Kong) Pharma Co. Ltd. ("Xinogen"), a wholly-owned subsidiary of Beijing Shenogen Pharma Group Ltd. entered a license and collaboration agreement to develop and commercialize ANG1005 in China for treatment of patients with leptomeningeal carcinomatosis from breast cancer. Xinogen was granted exclusive rights to develop and commercialize ANG1005 in the Greater China region. In return, Angiochem will receive upfront and milestone payments as well as a royalty based on future product sales. |
|
|
|
| Source:http://www.marketwired.com/mw/release.do?id=2244051&sourceType=3 |
| |
|
Related News
|
» Talonvest Capital Procures Refinance Loan for Class A Office Building
» Triloma EIG Energy Income Funds Invest in ARB Midstream, LLC
|
|
|
